National Bank of Canada FI Has $150.83 Million Holdings in Boston Scientific Corporation $BSX

National Bank of Canada FI raised its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 61.3% in the second quarter, according to its most recent 13F filing with the SEC. The fund owned 1,404,301 shares of the medical equipment provider’s stock after purchasing an additional 533,854 shares during the period. National Bank of Canada FI owned approximately 0.09% of Boston Scientific worth $150,828,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Vanguard Group Inc. boosted its position in shares of Boston Scientific by 1.9% during the second quarter. Vanguard Group Inc. now owns 137,134,110 shares of the medical equipment provider’s stock valued at $14,729,575,000 after buying an additional 2,545,381 shares during the last quarter. State Street Corp lifted its stake in Boston Scientific by 1.1% during the 2nd quarter. State Street Corp now owns 65,191,864 shares of the medical equipment provider’s stock valued at $7,002,258,000 after acquiring an additional 713,379 shares in the last quarter. Geode Capital Management LLC boosted its holdings in Boston Scientific by 2.0% during the 2nd quarter. Geode Capital Management LLC now owns 32,424,982 shares of the medical equipment provider’s stock worth $3,466,320,000 after acquiring an additional 622,602 shares during the last quarter. Norges Bank bought a new stake in shares of Boston Scientific in the 2nd quarter worth $2,089,937,000. Finally, Invesco Ltd. grew its stake in shares of Boston Scientific by 1.4% in the 2nd quarter. Invesco Ltd. now owns 16,851,518 shares of the medical equipment provider’s stock worth $1,810,022,000 after acquiring an additional 226,578 shares in the last quarter. 89.07% of the stock is owned by hedge funds and other institutional investors.

Boston Scientific Trading Up 0.9%

NYSE:BSX opened at $92.58 on Friday. Boston Scientific Corporation has a 12 month low of $85.98 and a 12 month high of $109.50. The company has a current ratio of 1.51, a quick ratio of 0.96 and a debt-to-equity ratio of 0.47. The firm’s 50 day moving average is $98.85 and its 200 day moving average is $101.61. The stock has a market capitalization of $137.24 billion, a PE ratio of 49.51, a price-to-earnings-growth ratio of 1.86 and a beta of 0.67.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.71 by $0.04. The business had revenue of $5.07 billion during the quarter, compared to the consensus estimate of $4.97 billion. Boston Scientific had a return on equity of 19.46% and a net margin of 14.43%.The business’s revenue for the quarter was up 20.3% on a year-over-year basis. During the same period last year, the business posted $0.63 earnings per share. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. Sell-side analysts expect that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Insider Buying and Selling

In other news, EVP Arthur C. Butcher sold 17,313 shares of Boston Scientific stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $101.55, for a total value of $1,758,135.15. Following the completion of the transaction, the executive vice president owned 23,600 shares in the company, valued at $2,396,580. This trade represents a 42.32% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the company’s stock in a transaction that occurred on Monday, November 3rd. The shares were sold at an average price of $99.47, for a total transaction of $4,973,500.00. Following the sale, the executive vice president owned 178,342 shares in the company, valued at $17,739,678.74. The trade was a 21.90% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 143,095 shares of company stock valued at $14,228,950. 0.50% of the stock is owned by insiders.

Analyst Ratings Changes

Several research analysts recently weighed in on BSX shares. Morgan Stanley boosted their price target on shares of Boston Scientific from $125.00 to $130.00 and gave the stock an “overweight” rating in a report on Thursday, October 23rd. Royal Bank Of Canada restated an “outperform” rating and issued a $125.00 target price on shares of Boston Scientific in a research note on Monday, September 29th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $132.00 price target on shares of Boston Scientific in a research report on Thursday, October 23rd. Erste Group Bank lowered Boston Scientific from a “buy” rating to a “hold” rating in a report on Friday, October 3rd. Finally, Needham & Company LLC reissued a “buy” rating and issued a $121.00 price objective on shares of Boston Scientific in a research report on Friday, October 17th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $124.43.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.